This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
A five-day inspection was concluded successfully with no critical and no major observations raised
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
The bioprocess business will continue to pioneer contributions to safety and productivity in the manufacture of biotherapeutics
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Subscribe To Our Newsletter & Stay Updated
